News

Currently, mipomersen is in late-stage development for the reduction of LDL cholesterol (LDL-C). Genzyme and Isis Pharma said that if approved the drug will be marketed under Kynamro

The joint venture which will focus on developing, manufacturing and promoting generic drugs, will be 51% owned by Fujifilm and 49% by the Indian drug maker. The new

Chasse-sur-Rhone provides for process scale-ups, the supply of clinical batches and the regular production of low volume compounds under cGMP. Freeport site performs custom manufacturing services from late

The tie up allows Ironwood to develop and commercialize the product, however Depomed will help in initial product formulation. As per the terms of the deal, Depomed is

Mylan‘s net earnings were $146.99m, compared to $86.93m for the same period in the prior year. The company has posted earnings from operations as $280.47m for the second

Genedata Expressionist for MS processes large experimental data sets of GC- and LC-MS (/MS), labeled and unlabeled – regardless of data formats. Each technology workflow requires specific pre-processing

The company has bought a 16mm and an 18mm Leistritz twin screw extruders. With this new HME, the company is now eligible to conduct feasibility studies by using

Dr Reddy’s Gemcitabine for Injection is the generic version of a cancer medication, Gemzar. Gemzar is indicated as a treatment for cancers of the pancreas, lung and breast

With this license extension application, the company is seeking marketing approval from the EMA for Zonegran as a monotherapy for patients suffering from epilepsy with partial seizures, with